Gritstone highlights durability, potential utility of samRNA COVID-19 vaccine

Gritstone bio presented updated Phase 1 data from its CORAL-CEPI study, a Coalition for Epidemic Preparedness Innovations-funded study that is evaluating Gritstone’s self-amplifying mRNA, samRNA, vaccine against COVID-19 in HIV-negative and people living with HIV, PLWH, participants. The presentation, at ESCMID Global 2024, reviewed the latest findings demonstrating the durability and potential broad utility of Gritstone’s samRNA vaccine against COVID-19. The new findings came from Group D, which evaluated immunogenicity of Gritstone’s samRNA vaccine candidate delivering the Spike BA.1 variant as compared to the Spike Beta variant evaluated in Groups A-C. “The data presented at ESCMID Global, our most comprehensive Phase 1 dataset to date, highlights the potential of our samRNA vaccine to generate robust and durable immune responses across a diverse set of populations; naive, convalescent and previously vaccinated,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio. “Previously, we had shown our samRNA vaccine capable of driving potentially broad and durable protection through 12 months across three Phase 1 studies spanning multiple other populations and settings. The new findings announced today demonstrate the vaccine is capable of driving broad and durable B and T cell responses in previously unvaccinated or vaccinated individuals in South Africa, including in people living with HIV. These results add to the growing body of evidence suggesting this differentiated immune response extends beyond healthy individuals and potentially to the most vulnerable of patients.”